At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 90 enrolled
Drug / intervention
NWP09 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Dose-optimized, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy Of Nwp09 In Pediatric Patients With Attention Deficit Hyperactivity Disorder (Adhd) In A Laboratory Classroom
In Brief
A Phase 3 clinical trial evaluating NWP09 and Placebo for Attention Deficit Hyperactivity Disorder. Completed, enrolled 90 participants across 9 sites.
Detailed Summary
The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedJul 2012
Primary CompletionOct 2012
TodayJul 2026
First PostedJul 31, 2012
Enrollment StartJul 1, 2012
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.9 years ago
Interventions
NWP09drug
Methylphenidate, variable dose, daily dosing, 1 week duration
Placebodrug
Placebo